Aadi Bioscience Inc reports results for the quarter ended in December - Earnings Summary

Whitehawk Therapeutics

13/03/2024 14:09

* Aadi Bioscience Inc  AADI.OQ  reported a quarterly
adjusted loss
of 60 cents​​ per share for the quarter ended in December, lower
than the same quarter last year, when the company reported EPS
of -52 cents.  The mean expectation of five analysts for the
quarter was for a loss of 65 cents per share. Wall Street
expected results to range from -73 cents to -58 cents per share.
    * Revenue rose 19.9% to $6.33 million from a year ago;
analysts
expected $6.29 million. 
    * Aadi Bioscience Inc's reported EPS for the quarter was a
loss
of 60 cents​.
    * The company reported a quarterly loss of $16.27 million.
    * Aadi Bioscience Inc shares had fallen by 4.0% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Aadi Bioscience
Inc is $14.00 
This summary was machine generated from LSEG data March 13 at
02:09 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.65          -0.60          Beat
 Sep. 30 2023      -0.72          -0.60          Beat
 Jun. 30 2023      -0.62          -0.67          Missed
 Mar. 31 2023      -0.58          -0.57          Beat